Tin tức & Cập nhật

In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).

A response-tailored strategy decreases antibiotic duration by 2 weeks compared with standard therapy in patients with left-sided infective endocarditis, without compromising their safety. This is the primary result of the POET-II study presented at ESC Congress 2026.

In the global phase III frontMIND study, adding tafasitamab and lenalidomide (Tafa-Len) to an R-CHOP* chemotherapy regimen significantly improves progression-free survival in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade BCL (HGBCL).

Long-term survival benefits with tebentafusp persist in previously untreated HLA-A∗02:01-positive patients with unresectable or metastatic uveal melanoma (mUM), as shown in the longest survival follow-up of a phase III trial.

First-line treatment with lorlatinib demonstrates long-term survival benefits in patients with advanced anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), as shown in the 7-year update from the phase III CROWN study.

Four-year updates from the CHIEF study show a durable survival benefit with atezolizumab plus bevacizumab in individuals with advanced hepatocellular carcinoma (HCC).